---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-056048"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T07:15:16.937915+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Appoints Michael King as CFO with $450K salary and 850K share option grant

## Summary
- Michael King appointed CFO effective Oct 30, 2023; Russell Beyer ceased as CFO on Oct 27.
- Base salary $450,000, target annual bonus of 40% of base, and 850,000 stock options.
- Options vest over 4 years: 25% on 1-year anniversary, then monthly over 36 months.
- King has 25+ years in biotech research; most recently Co-Head of Healthcare at EF Hutton.
- No family relationships or arrangements with others influenced his selection.

## SEC filing metadata
- accession: 0000950170-23-056048
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/sabs-20231023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-056048
- JSON: https://secwatch.observer/filing/0000950170-23-056048.json
- Plain text: https://secwatch.observer/filing/0000950170-23-056048.txt

## Key facts
- Executive change
  Michael King was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Michael King, age 62, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective October 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm
- Executive change
  Russell P. Beyer departed as Chief Financial Officer at SAB Biotherapeutics, Inc..
  - Action: ceased
  - Role: Chief Financial Officer
  source text: Russell P. Beyer ceased to serve as Chief Financial Officer of the Company on October 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017023056048/0000950170-23-056048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.